Patients in each active treatment group demonstrated a progressive increase in walking distances over time, with the greatest improvement observed in patients who received cilostazol (Figure 1).

Current guidelines lack recommendations regarding the use of proton pump inhibitors (PPIs) for preventing upper gastrointestinal bleeding (UGIB) among patients at low risk for UGIB treated with dual ...